ALDX — Aldeyra Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1341235 ·
Last close
$0.95
Market Cap
$57.17M
52W High
$5.93
52W Low
$0.86
ADV30
1,420,880
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -5,850,507 | -5,450,273 | 47,540,559 | 45,089,786 | 9,655,256 |
| Mar 2026 | 0 | — | -3,546,918 | -3,452,619 | 66,483,081 | 65,002,305 | 24,326,289 |
| Dec 2025 | 0 | — | -6,667,883 | -6,461,507 | 72,059,317 | 70,041,254 | 27,808,927 |
| Sep 2025 | 0 | — | -8,001,132 | -7,688,341 | 77,801,012 | 59,340,599 | 28,556,469 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-22,020,272
Investing CF
$40,976,903
Financing CF
$-15,108,114
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.44
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-492,860,145
Inventory
—
Receivables
$755,545
ST Investments
$0
EBIT TTM
$-21,632,877
Pretax Income TTM
$-23,052,740
Interest Exp TTM
$1,419,863
Analysts
5
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -35,265,206 | -33,846,661 | 72,059,317 | 27,808,927 | 44,250,390 | -33,345,682 |
| Dec 2024 | 0 | -60,117,032 | -55,851,444 | 104,606,694 | 33,601,823 | 71,004,871 | -43,208,747 |
| Dec 2023 | 0 | -42,794,083 | -37,542,510 | 148,326,911 | 28,531,881 | 119,795,030 | -30,326,128 |
| Dec 2022 | 0 | -62,679,987 | -62,024,636 | 181,291,657 | 30,283,628 | 151,008,029 | -56,637,187 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$2,905,345
NetIncome TTM
$-27,369,779
OpCashFlow TTM
—
Assets (Latest)
$66,483,081
Forward EPS
$-0.28
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.00 · spot: $0.93 · call volume: 23 · put volume: 102
Expected Move to 2026-12-18:
±$0.85
(91.38%) —
implied range
$0.08 –
$1.78
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PDSB | PDS Biotechnology Corp | $57.09M | $1.02 | — |
| TLPH | TALPHERA, INC. | $56.06M | $1.08 | — |
| ATHE | ALTERITY THERAPEUTICS LTD | $55.90M | $3.07 | — |
| BOLD | Boundless Bio, Inc. | $58.69M | $2.58 | — |
| CNTB | Connect Biopharma Holdings Ltd | $55.46M | $0.88 | — |
News headlines (Yahoo Finance, 1h cache)
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease
2026-09-29 15:02 · Yahoo
Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter
2026-09-29 14:49 · Yahoo
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
2026-09-29 11:00 · Yahoo
Aldeyra Therapeutics to Host Regulatory Update Webcast
2026-09-28 20:30 · Yahoo
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
2026-10-09 16:55 · Yahoo
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
2026-10-09 14:53 · Yahoo
Here's Why You Should Add LPCN Stock to Your Portfolio Now
2026-10-08 13:57 · Yahoo
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
2026-10-08 13:49 · Yahoo
ETON Stock Surges 108% in Six Months: Here's What You Need to Know
2026-10-07 15:08 · Yahoo
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
2026-10-06 13:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.